Novo Nordisk will establish a type 1 diabetes R&D center in Seattle, WA. The new center will combine the company’s diabetes expertise with its growing immunotherapy expertise. The center is expected to open this summer and will be staffed by approximately 20 researchers who will be supported by corporate functions in the U.S. and Denmark. The new center aims to pursue a translational research approach by combining basic research and early proof-of-concept trials under one umbrella. This wil...